







Studies	Janssen JNJ-ALZ2002	VIVA-MIND	Roche SKYLINE	Alnylam ALN-APP-001	AVANIR ASPECT AVP-786	Alector AL001-3
Required Diagnosis	Prodromal/Early Alzheimer's Disease	MCI due to AD, or mild Alzheimer's Disease	Can NOT have dx of MCI, prodromal AD, or other dementias	MCI or AD due to early onset (onset age <65)	Probable Alzheimer's Disease & moderate-to-severe agitation	Frontotemporal Dementia and progranulin gene mutation
Phase	2	2A/2B	3	1	3	3
Route of Therapy Administration	Infusion	Oral tablet	Subcutaneous injection to the abdomen	Intrathecal injection	Oral tablet	Infusion
Age	55 - 80 (inclusive)	50 - 89 (inclusive)	60 -80 (inclusive)	18 and older	50 - 90 (inclusive)	25 - 85 (inclusive)
Length	Up to 5 yrs	Min. of 24 wks	4 yrs 9 mos	Up to 14 mos (Part A) Up to 24 mos (Part B)	Up to 14 wks	Up to 27 mos
Lumbar Puncture	Optional	Yes	Optional	10+ times	No	Optional
MRI	Required	Required	Required	Required	No	Required
Amyloid PET	No	No	Required	Required	No	No
Tau PET	Required	No	Required	Optional	No	No
Compensation	Yes	Yes	Yes	Yes	Yes	Yes
Read more on clinicaltrials.gov	 Identifier: NCT04619420	 Identifier: NCT03919162	 Identifier: NCT05256134	 Identifier: NCT05231785	 Identifier: NCT03393520	 Identifier: NCT04374136

Required for all drug studies: Must have a study partner; No recent changes in AD medications or doses; No history of medical conditions other than the required diagnosis (e.g., AD, FTD) that could account for cognitive deficits.

FOR ALL STUDIES, PLEASE CONTACT clinicaltrialsADRC@health.ucsd.edu for more details